From: Rivaroxaban for the treatment of cerebral venous thrombosis
Clinical findings | All patients (36) | Warfarin (13) | Rivaroxaban (23) | P value |
---|---|---|---|---|
Duration of hospitalization (days) | 16.77 ± 10.69 | 11.7 ± 7.61 | 0.133 | |
Loss of consciousness | 7 (19.44%) | 0.382 | ||
Yes | 1 (7.7%) | 6 (26.1%) | ||
No | 12 (92.3%) | 17 (73.9%) | ||
Outcomes of treatment | ||||
Minor bleeding | 5 (15.63%) | 2/10 (20%) | 3/22 (13.63) | 0.708 |
Major bleeding | 0 | 0 | 0 | |
mRS | 32a | 10 | 22 | > 0.999 |
mRS (0 or 1) | 28 (87.5%) | 9 (90%) | 19 (86.36%) | |
mRS 2 | 4 (12.5%) | 1 (10%) | 3 (13.63%) | |
MRV (Recanalization) | 19a | 5 | 14 | > 0.999 |
Recanalized | 17 (93.75%) | 5 (100%) | 12 (85.71%) | |
Complete | 14 (84.37%) | 4 (80%) | 10 (83.33%) | |
Partial | 3 (9.38%) | 1 (20%) | 2 (16.67%) | |
Not recanalized | 2 (6.25%) | 0 | 2 (14.29%) |